A new rule posted on the Office of Management and Budget (OMB) registry suggests that the Drug Enforcement Administration (DEA) is planning an additional extension of COVID-19 flexibilities for telemedicine prescribing of controlled substances, beyond the current expiration date of December 31, 2024.
The new rule is entitled “Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications” and is not yet available for public review. Rules must clear OMB review before being published in the Federal Register; there is no minimum period for this review.